Neuroblastoma, a common childhood tumor, remains one of the most elusive diseases to treat. To date, high-risk neuroblastoma is associated with low survival rates. To address this, novel and more effective therapeutic strategies must continue to be explored.
We employed a bioinformatics approach corroborated with in vitro and in vivo data. Samples from neuroblastoma patients were retrieved and immuno-stained for Bruton’s tyrosine kinase (BTK). To evaluate its effect on cellular functions, BTK expression in SK-N-BE(2) and SH-SY5Y neuroblastoma cells was downregulated using gene silencing or inhibition with ibrutinib or acalabrutinib. Xenograft mouse models were used to investigate the in vivo role of BTK in neuroblastoma tumorigenesis.
We found that BTK was highly expressed in primary neuroblastoma samples, preferentially in MYCN-amplified neuroblastoma cases, and was associated with a poor prognosis. Immunohistochemical staining of tissues from our neuroblastoma cohort revealed a strong BTK immunoreactivity. We also found that neuroblastoma SK-N-BE(2) and SH-SY5Y cells were sensitive to treatment with ibrutinib and acalabrutinib. Pharmacologic or molecular inhibition of BTK elicited a reduction in the migratory and invasive abilities of neuroblastoma cells, and ibrutinib considerably attenuated the neurosphere-forming ability of neuroblastoma cells. Both inhibitors showed synergism with cisplatin. In vivo assays showed that acalabrutinib effectively inhibited neuroblastoma tumorigenesis.
From our data we conclude that BTK is a therapeutically targetable driver of neuroblastoma.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
The datasets used and analyzed in the study are available from the corresponding author upon reasonable requests.
M.A. Smith, S.F. Altekruse, P.C. Adamson, G.H. Reaman, N.L. Seibel, Declining childhood and adolescent cancer mortality. Cancer 120, 2497–2506 (2014). doi:https://doi.org/10.1002/cncr.28748
K.K. Matthay, J.M. Maris, G. Schleiermacher, A. Nakagawara, C.L. Mackall, L. Diller, W.A. Weiss, Neuroblastoma. Nature reviews. Dis. Prim. 2, 16078 (2016). https://doi.org/10.1038/nrdp.2016.78
D. Hanahan, R.A. Weinberg, Hallmarks of cancer: the next generation Cell 144, 646–674 (2011). https://doi.org/10.1016/j.cell.2011.02.013
J.A. Burger, A. Wiestner, Targeting b cell receptor signalling in cancer: Preclinical and clinical advances. Nat. Rev. Cancer 18, 148–167 (2018). https://doi.org/10.1038/nrc.2017.121
A. Wiestner, The role of b-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. Haematologica 100, 1495–1507 (2015). https://doi.org/10.3324/haematol.2014.119123
A. Wiestner, Clinical trial data on the BTK pathway in b-cell malignancies. Clin. Adv. Hematol. & Oncol. 11 (Suppl 9), 6–10 (2013)
A. Paulus, S. Akhtar, H. Yousaf, A. Manna, S.M. Paulus, Y. Bashir, T.R. Caulfield, M. Kuranz-Blake, K. Chitta, X. Wang, Y. Asmann, R. Hudec, W. Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. Springer, S. Ailawadhi and A. Chanan-Khan, Blood Cancer J. 7, e565 (2017). https://doi.org/10.1038/bcj.2017.40
K. Kondo, H. Shaim, P.A. Thompson, J.A. Burger, M. Keating, Z. Estrov, D. Harris, E. Kim, A. Ferrajoli, M. Daher, R. Basar, M. Muftuoglu, N. Imahashi, A. Alsuliman, C. Sobieski, E. Gokdemir, W. Wierda, N. Jain, E. Liu, E.J. Shpall, K. Rezvani, Ibrutinib modulates the immunosuppressive cll microenvironment through stat3-mediated suppression of regulatory b-cell function and inhibition of the pd-1/pd-l1 pathway. Leukemia 32, 960–970 (2018). https://doi.org/10.1038/leu.2017.304
R.W. Hendriks, S. Yuvaraj, L.P. Kil, Targeting bruton’s tyrosine kinase in b cell malignancies. Nat. Rev. Cancer 14, 219–232 (2014). https://doi.org/10.1038/nrc3702
Y. Qiu, H.J. Kung, Signaling network of the BTK family kinases. Oncogene 19, 5651–5661 (2000). https://doi.org/10.1038/sj.onc.1203958
P.A. Thompson, J.A. Burger, Bruton’s tyrosine kinase inhibitors: First and second generation agents for patients with chronic lymphocytic leukemia (cll). Expert. Opin. Investig. Drugs 27, 31–42 (2018). https://doi.org/10.1080/13543784.2018.1404027
H. Qin, G. Wei, I. Sakamaki, Z. Dong, W.A. Cheng, D.L. Smith, F. Wen, H. Sun, K. Kim, S. Cha, L. Bover, S.S. Neelapu, L.W. Kwak, Novel baff-receptor antibody to natively folded recombinant protein eliminates drug-resistant human b-cell malignancies in vivo. Clin. Cancer Res. 24, 1114–1123 (2018). https://doi.org/10.1158/1078-0432.CCR-17-1193
Y. Ge, C. Wang, S. Song, J. Huang, Z. Liu, Y. Li, Q. Meng, J. Zhang, J. Yao, K. Liu, X. Ma, X. Sun, Identification of highly potent BTK and jak3 dual inhibitors with improved activity for the treatment of b-cell lymphoma. Eur. J. Med. Chem. 143, 1847–1857 (2018). https://doi.org/10.1016/j.ejmech.2017.10.080
T. Yano, Chronic lymphocytic leukemia: Biology, disease progression, and current treatment strategies. Jpn. J. Clin. Hematol. 58, 1960–1972 (2017). https://doi.org/10.11406/rinketsu.58.1960
K. Izutsu, Treatment for mantle cell lymphoma. Jpn. J. Clin Hematol. 58, 2026–2032 (2017). https://doi.org/10.11406/rinketsu.58.2026
J. Wu, M. Zhang, D. Liu, Bruton tyrosine kinase inhibitor ono/gs-4059: From bench to bedside. Oncotarget 8, 7201–7207 (2017). https://doi.org/10.18632/oncotarget.12786
J.J. Castillo, S.P. Treon, M.S. Davids, Inhibition of the bruton tyrosine kinase pathway in b-cell lymphoproliferative disorders. Cancer J. 22, 34–39 (2016). https://doi.org/10.1097/PPO.0000000000000170
M.R. Smith, Ibrutinib in b lymphoid malignancies. Expert Opin. Pharmacother. 16, 1879–1887 (2015). https://doi.org/10.1517/14656566.2015.1067302
V. Patel, K. Balakrishnan, E. Bibikova, M. Ayres, M.J. Keating, W.G. Wierda, V. Gandhi, Comparison of acalabrutinib, a selective bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia Cells. Clin. Cancer Res. 23, 3734–3743 (2017). https://doi.org/10.1158/1078-0432.CCR-16-1446
W. Guo, R. Liu, G. Bhardwaj, J.C. Yang, C. Changou, A.H. Ma, A. Mazloom, S. Chintapalli, K. Xiao, W. Xiao, P. Kumaresan, E. Sanchez, C.T. Yeh, C.P. Evans, R. Patterson, K.S. Lam, H.J. Kung, Targeting BTK/etk of prostate cancer cells by a novel dual inhibitor. Cell. Death Dis. 5, e1409 (2014). https://doi.org/10.1038/cddis.2014.343
M.A. Zucha, A.T. Wu, W.H. Lee, L.S. Wang, W.W. Lin, C.C. Yuan, C.T. Yeh, Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer. Oncotarget 6, 13255–13268 (2015). https://doi.org/10.18632/oncotarget.3658
A.J. Gunderson, M.M. Kaneda, T. Tsujikawa, A.V. Nguyen, N.I. Affara, B. Ruffell, S. Gorjestani, S.M. Liudahl, M. Truitt, P. Olson, G. Kim, D. Hanahan, M.A. Tempero, B. Sheppard, B. Irving, B.Y. Chang, J.A. Varner, L.M. Coussens, Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer. Cancer Discov. 6, 270–285 (2016). https://doi.org/10.1158/2159-8290.CD-15-0827
L. Ping, N. Ding, Y. Shi, L. Feng, J. Li, Y. Liu, Y. Lin, C. Shi, X. Wang, Z. Pan, Y. Song, J. Zhu, The bruton’s tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages. Oncotarget 8, 39218–39229 (2017). https://doi.org/10.18632/oncotarget.16836
M. Ito, T. Shichita, M. Okada, R. Komine, Y. Noguchi, A. Yoshimura, R. Morita, Bruton’s tyrosine kinase is essential for nlrp3 inflammasome activation and contributes to ischaemic brain injury. Nat. Commun. 6, 7360 (2015). https://doi.org/10.1038/ncomms8360
L. Wei, Y.K. Su, C.M. Lin, T.Y. Chao, S.P. Huang, T.T. Huynh, H.J. Jan, J. Whang-Peng, J.F. Chiou, A.T. Wu, M. Hsiao, Preclinical investigation of ibrutinib, a bruton’s kinase tyrosine (BTK) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes. Oncotarget 7, 69961–69975 (2016). https://doi.org/10.18632/oncotarget.11572
E.J. Yang, J.H. Yoon, K.C. Chung, Bruton’s tyrosine kinase phosphorylates camp-responsive element-binding protein at serine 133 during neuronal differentiation in immortalized hippocampal progenitor cells. J. Biol. Chem. 279, 1827–1837 (2004). https://doi.org/10.1074/jbc.M308722200
T. Li, Y. Deng, Y. Shi, R. Tian, Y. Chen, L. Zou, J.U. Kazi, L. Ronnstrand, B. Feng, S.O. Chan, W.Y. Chan, J. Sun, H. Zhao, Bruton’s tyrosine kinase potentiates alk signaling and serves as a potential therapeutic target of neuroblastoma. Oncogene 37, 6180–6194 (2018). https://doi.org/10.1038/s41388-018-0397-7
W. Allen-Rhoades, S.B. Whittle, N. Rainusso, Pediatric solid tumors of infancy: An overview. Pediatr. Rev. 39, 57–67 (2018). https://doi.org/10.1542/pir.2017-0057
V. Vichai, K. Kirtikara, Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat. Protoc. 1, 1112–1116 (2006). https://doi.org/10.1038/nprot.2006.179
J. Koster, R2: Genomics Analysis and Visualization Platform http://www.r2.amc.nl. (2011)
J.J. Molenaar, J. Koster, D.A. Zwijnenburg, P. van Sluis, L.J. Valentijn, I. van der Ploeg, M. Hamdi, J. van Nes, B.A. Westerman, J. van Arkel, M.E. Ebus, F. Haneveld, A. Lakeman, L. Schild, P. Molenaar, P. Stroeken, M.M. van Noesel, I. Ora, E.E. Santo, H.N. Caron, E.M. Westerhout, R. Versteeg, Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 483, 589–593 (2012). https://doi.org/10.1038/nature10910
J.R. Park, A. Eggert, H. Caron, Neuroblastoma: Biology, prognosis, and treatment. Hematol. Oncol. Clin. North Am. 24, 65–86 (2010). https://doi.org/10.1016/j.hoc.2009.11.011
J. Molina-Cerrillo, T. Alonso-Gordoa, P. Gajate, E. Grande, Bruton’s tyrosine kinase (BTK) as a promising target in solid tumors. Cancer Treat. Rev. 58, 41–50 (2017). https://doi.org/10.1016/j.ctrv.2017.06.001
I. Sagiv-Barfi, H.E. Kohrt, D.K. Czerwinski, P.P. Ng, B.Y. Chang, R. Levy, Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and itk. Proc. Natl. Acad. Sci. U.S.A. 112, E966–E972 (2015). https://doi.org/10.1073/pnas.1500712112
H. Shimada, I.M. Ambros, L.P. Dehner, J. Hata, V.V. Joshi, B. Roald, D.O. Stram, R.B. Gerbing, J.N. Lukens, K.K. Matthay, R.P. Castleberry, The international neuroblastoma pathology classification (the shimada system). Cancer 86, 364–372 (1999)
H.Y. Tan, N. Wang, W. Lam, W. Guo, Y. Feng, Y.C. Cheng, Targeting tumour microenvironment by tyrosine kinase inhibitor. Mol. Cancer 17, 43 (2018). https://doi.org/10.1186/s12943-018-0800-6
Y.P. Hu, Z.B. Wu, L. Jiang, Y.P. Jin, H.F. Li, Y.J. Zhang, Q. Ma, Y.Y. Ye, Z. Wang, Y.C. Liu, H.Z. Chen, Y.B. Liu, Styk1 promotes cancer cell proliferation and malignant transformation by activating pi3k-akt pathway in gallbladder carcinoma. Int. J. Biochem. Cell Biol. 97, 16–27 (2018). https://doi.org/10.1016/j.biocel.2018.01.016
W. Xu, Z. Yang, N. Lu, A new role for the pi3k/akt signaling pathway in the epithelial-mesenchymal transition. Cell Adhes. Migr. 9, 317–324 (2015). https://doi.org/10.1080/19336918.2015.1016686
S.P. Singh, S.Y. Pillai, M.J.W. de Bruijn, R. Stadhouders, O.B.J. Corneth, H.J. van den Ham, A. Muggen, I.W.E. van Slinger, A. Kuil, M. Spaargaren, A.P. Kater, A.W. Langerak, R.W. Hendriks, Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive BTK and akt signaling. Oncotarget 8, 71981–71995 (2017). https://doi.org/10.18632/oncotarget.18234
T.K. Moyo, C.S. Wilson, D.J. Moore, C.M. Eischen, Myc enhances b-cell receptor signaling in precancerous b cells and confers resistance to BTK inhibition. Oncogene 36, 4653–4661 (2017). https://doi.org/10.1038/onc.2017.95
Y. Yang, J. Shi, Z. Gu, M.E. Salama, S. Das, E. Wendlandt, H. Xu, J. Huang, Y. Tao, M. Hao, R. Franqui, D. Levasseur, S. Janz, G. Tricot, F. Zhan, Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma. Cancer Res. 75, 594–604 (2015). https://doi.org/10.1158/0008-5472.CAN-14-2362
S.K. Tripathi, Z. Chen, A. Larjo, K. Kanduri, K. Nousiainen, T. Aijo, I. Ricano-Ponce, B. Hrdlickova, S. Tuomela, E. Laajala, V. Salo, V. Kumar, C. Wijmenga, H. Lahdesmaki, R. Lahesmaa, Genome-wide analysis of stat3-mediated transcription during early human th17 cell differentiation. Cell Rep. 19, 1888–1901 (2017). https://doi.org/10.1016/j.celrep.2017.05.013
K. Hawkins, L. Mohamet, S. Ritson, C.L. Merry, C.M. Ward, E-cadherin and, in its absence, n-cadherin promotes nanog expression in mouse embryonic stem cells via stat3 phosphorylation. Stem Cells 30, 1842–1851 (2012). https://doi.org/10.1002/stem.1148
J. Hall, G. Guo, J. Wray, I. Eyres, J. Nichols, L. Grotewold, S. Morfopoulou, P. Humphreys, W. Mansfield, R. Walker, S. Tomlinson, A. Smith, Oct4 and lif/stat3 additively induce kruppel factors to sustain embryonic stem cell self-renewal. Cell Stem Cell 5, 597–609 (2009). https://doi.org/10.1016/j.stem.2009.11.003
P. Zhang, R. Andrianakos, Y. Yang, C. Liu, W. Lu, Kruppel-like factor 4 (klf4) prevents embryonic stem (es) cell differentiation by regulating nanog gene expression. J. Biol. Chem. 285, 9180–9189 (2010). https://doi.org/10.1074/jbc.M109.077958
X. Wang, J. Wong, C.J. Sevinsky, L. Kokabee, F. Khan, Y. Sun, D.S. Conklin, Bruton’s tyrosine kinase inhibitors prevent therapeutic escape in breast cancer cells. Mol. Cancer Ther. 15, 2198–2208 (2016). https://doi.org/10.1158/1535-7163.MCT-15-0813
Y. Li, N. Cui, P.S. Zheng, W.T. Yang, BMX/Etk promotes cell proliferation and tumorigenicity of cervical cancer cells through PI3K/AKT/mTOR and STAT3 pathways. Oncotarget 8, 49238–49252 (2017). https://doi.org/10.18632/oncotarget.17493
J. Cidado, H.Y. Wong, D.M. Rosen, A. Cimino-Mathews, J.P. Garay, A.G. Fessler, Z.A. Rasheed, J. Hicks, R.L. Cochran, S. Croessmann, D.J. Zabransky, M. Mohseni, J.A. Beaver, D. Chu, K. Cravero, E.S. Christenson, A. Medford, A. Mattox, A.M. De Marzo, P. Argani, A. Chawla, P.J. Hurley, J. Lauring, B.H. Park, Ki-67 is required for maintenance of cancer stem cells but not cell proliferation. Oncotarget 7, 6281–6293 (2016). https://doi.org/10.18632/oncotarget.7057
The authors thank the research assistants at the Core Facility Center, Department of Medical Research, Taipei Medical University - Shuang Ho Hospital, especially Mr. Iat-Hang Fong and Mr. Sam Huang, for their technical assistance with cell-based assays. The authors also thank Dr. Alexander TH Wu and Mr. Oliver Huang for their interest and constructive advice in the animal experimental designs and their skillful technical support of this project. This manuscript was edited by Wallace Academic Editing.
This work was supported by the National Science Council of Taiwan: Tsu-Yi Chao (MOST105-2314-B038-080 and MOST 108-2314-B-038-051-MY3). It was also supported by a grant from National Taiwan University Hospital: Wen-Ming Hsu (107-S3825).
Ethics approval and consent to participate
Clinical samples were collected from the National Taiwan University Hospital (Taipei City, Taiwan). All enrolled patients gave written informed consent for their tissues to be used for scientific research. The study was approved by the Joint Institutional Review Board of National Taiwan University Hospital (201705121RIND), consistent with the recommendations of the Declaration of Helsinki for biomedical research.
Conflict of interest
The authors have declared no conflicts of interest. The authors declare that they have no potential financial competing interests that may in any way gain or lose financially from the publication of this manuscript at present or in the future. Additionally, no nonfinancial competing interests are involved in the manuscript.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
• Bruton’s Tyrosine Kinase (BTK) is highly expressed in neuroblastoma
• High BTK expressing tumors is associated with poorer prognosis
• BTK inhibitor, Ibrutinib, reduced neuroblastoma cells migration and invasion ability
• Ibrutinib also lowered Neuro-sphere formation potential of neuroblastoma cells
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Pikatan, N.W., Liu, YL., Bamodu, O.A. et al. Aberrantly expressed Bruton’s tyrosine kinase preferentially drives metastatic and stem cell-like phenotypes in neuroblastoma cells. Cell Oncol. 43, 1067–1084 (2020). https://doi.org/10.1007/s13402-020-00541-5
- Pediatric brain tumor
- Bruton’s tyrosine kinase
- Cancer stem cells